CNSX - New Listing - Abattis Biologix Corp. (FLU)

Bulletin: 2010-1211

TORONTO, Dec. 22 /CNW/ - The common shares of Abattis Biologix Corp. have been approved for listing on CNSX.  The Company has 49,640,500 common shares outstanding all of which is held by the public.

Abattis Biologix is engaged in the research, development and manufacture of natural botanical formulations which prevent or treat various influenza strains found in human, avian and mammalian populations. On April 16, 2009, the Company entered into an agreement with PRB Pharmaceuticals, Inc. and Pacific Bio-Pharmaceuticals, Inc. for the purchase of their interest in patents and intellectual property related to anti viral products designed to prevent avian influenza in humans and poultry.

Listing and disclosure documents for Abattis Biologix Corp. will be available in the CNSX Listings Disclosure Hall.

Trading Date: Thursday, December 23, 2010
Symbol: FLU
CUSIP: 00258E 10 8
ISIN: CA 00258E 10 8 8

Applications are being accepted for Market Makers for "FLU".

SOURCE Canadian National Stock Exchange (CNSX)

For further information: For further information:

Radhika at (416) 572-2000 X 2435 or E-mail:

Organization Profile

Canadian National Stock Exchange (CNSX)

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890